Vir jumps on positive data from early-stage trials for tumor treatments
08/01/2025 13:17
** Drug developer Vir Biotechnology's VIR.O shares rise
33.2% to $10.50 premarket
** Co says its drugs VIR-5818 and VIR-5500 showed compelling
response in patients with various solid tumors during
early-stage trials
** Says VIR-5818 showed tumor shrinkage in 50% of patients
with various HER2 positive cancers
** HER2 is a protein that stimulates quick growth of cancer
cells
** VIR says all 12 patients who took VIR-5500 showed a
decline in prostate-specific antigen levels, which indicate the
presence of prostate cancer
** Up to last close, stock down 25.6% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO